FDA clears Marker Therapeutics IND for MT-601 to treat pancreatic cancer

Marker Therapeutics, Inc.

FDA cleared IND for MT-601, a six-antigen T cell therapy for locally advanced unresectable or metastatic pancreatic cancer.
Phase 1 trial planned for 2023, combining MT-601 with front-line chemotherapy.
New manufacturing process reduces production time from >30 days to 9 days with 90% fewer interventions.
Interim TACTOPS study data showed multiTAA therapy plus chemo yielded better-than-expected clinical responses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.